Ovamex (Ganirelix)

Ganirelix, the active ingredient in Ovamex, is a GnRH antagonist presented as an injectable solution for subcutaneous use. It is employed to prevent premature luteinizing hormone surges during controlled ovarian stimulation in assisted reproductive technology cycles for women undergoing IVF, ICSI, or egg donation. It is administered as a single daily injection during the mid‑follicular phase and provides precise control over the timing of ovulation, enhancing the success rates of assisted reproduction.

GNH USA supplies Ovamex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics, and research centres worldwide.

Ganirelix is used in assisted reproductive technology to regulate the hormonal pathway that triggers ovulation.

- In vitro fertilization (IVF): prevents premature luteinizing hormone surge, allowing controlled follicular development. - Intracytoplasmic sperm injection (ICSI): supports synchronized follicle growth for optimal oocyte retrieval. - Egg donation cycles: facilitates timing of follicular maturation to match recipient cycles.

Ganirelix may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema - Nausea or mild abdominal discomfort - Headache - Hot flashes - Mild ovarian cyst formation - Transient fatigue

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe) - Allergic reaction including rash, pruritus, or anaphylaxis - Severe abdominal pain or pelvic infection - Thromboembolic events - Significant hormonal imbalance requiring medical intervention

When using Ganirelix, careful monitoring and patient assessment are essential.

- Pregnancy testing: confirm a negative result before initiating therapy. - Hormonal monitoring: perform regular ultrasound and estradiol assessments to guide dosing. - Allergy assessment: verify no hypersensitivity to ganirelix or formulation excipients. - Ovarian hyperstimulation syndrome: watch for signs of fluid shift or abdominal distension. - Drug interaction review: evaluate concomitant medications that affect hormonal balance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ganirelix can interact with other agents that influence the reproductive hormonal axis.

Major Interactions (Avoid): - GnRH agonist therapy: concurrent use may counteract antagonist effect. - High‑dose estrogen therapy: may reduce ganirelix efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for altered bleeding risk during ovarian stimulation. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase renal load when combined with hormonal therapy. - Other fertility drugs (e.g., recombinant FSH): adjust dosing to mitigate ovarian hyperstimulation risk.